332 related articles for article (PubMed ID: 21325999)
1. Transdermal opioids for cancer pain.
Cachia E; Ahmedzai SH
Curr Opin Support Palliat Care; 2011 Mar; 5(1):15-9. PubMed ID: 21325999
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O;
Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402
[TBL] [Abstract][Full Text] [Related]
4. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
6. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
7. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Tawfik MO; Bryuzgin V; Kourteva G;
Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
[TBL] [Abstract][Full Text] [Related]
8. Transdermal buprenorphine in cancer pain and palliative care.
Sittl R
Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218
[TBL] [Abstract][Full Text] [Related]
9. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
Mitra F; Chowdhury S; Shelley M; Williams G
Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
[TBL] [Abstract][Full Text] [Related]
10. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
11. Transdermal buprenorphine (Butrans) for chronic pain.
Med Lett Drugs Ther; 2011 Apr; 53(1362):31-2. PubMed ID: 21502936
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
13. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
14. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
[TBL] [Abstract][Full Text] [Related]
15. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
Kress HG
Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516
[TBL] [Abstract][Full Text] [Related]
16. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
Griessinger N; Sittl R; Likar R
Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
18. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
19. Transdermal therapeutic fentanyl-system (TTS-F).
Mystakidou K; Katsouda E; Tsilika E; Parpa E; Vlahos L
In Vivo; 2004; 18(5):633-42. PubMed ID: 15523905
[TBL] [Abstract][Full Text] [Related]
20. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies.
Louis F
Int J Clin Pract; 2006 Oct; 60(10):1330-4. PubMed ID: 16981980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
